Department of Biochemistry and Microbiology, Nelson Mandela Metropolitan University, Port Elizabeth 6031, South Africa.
J Ethnopharmacol. 2013 Mar 27;146(2):482-9. doi: 10.1016/j.jep.2013.01.008. Epub 2013 Feb 1.
The African medicinal plant Sutherlandia frutescens (L.) R.Br. (Fabaceae) is traditionally used to treat diabetes and has been shown to have anti-diabetic properties in animal models. The present study investigated the capacity of an aqueous extract of Sutherlandia frutescens to prevent insulin resistance (a precursor of type 2 diabetes) in a human liver cell culture and to identify genes regulated by Sutherlandia frutescens treatment.
A combination of insulin and fructose was used to generate an in vitro model of insulin resistance in human liver cells to compare untreated control, insulin resistant and Sutherlandia frutescens treated insulin resistant cultures. Insulin resistance and its prevention by Sutherlandia frutescens were measured by glucose uptake, gluconeogenesis and lipid accumulation in the cell cultures. Changes in gene expression were quantified using the RT(2)Profiler(TM) PCR Array of 84 diabetes-related genes.
The insulin resistant Chang liver cells took up significantly less 2-[(3)H]-deoxyglucose (p<0.05) than controls, released more glucose into the culture medium (p<0.05) and accumulated more intracellular lipid (p<0.05). Simultaneous treatment with Sutherlandia frutescens prevented development of these insulin resistance parameters (p<0.05). A total of 27 potential gene targets of Sutherlandia frutescens were significantly up or down regulated in the Sutherlandia frutescens treated insulin resistant cells. The gene VAMP3, which plays a role in vesicle transport, was down-regulated by insulin resistance, and up-regulated by Sutherlandia frutescens. Twenty six other genes encoding vesicle transporters, receptors, signalling molecules, transcription factors, and metabolic enzymes were significantly regulated by Sutherlandia frutescens.
These results confirm that Sutherlandia frutescens can prevent insulin resistance in hepatocytes. The identified changes in gene expression indicate several potential mechanisms of anti-diabetic action for Sutherlandia frutescens, reflecting the multiple bioactive compounds previously identified in aqueous extracts of Sutherlandia frutescens.
非洲药用植物南非钩麻(L.)R.Br.(豆科)传统上用于治疗糖尿病,并已在动物模型中显示出抗糖尿病特性。本研究调查了南非钩麻水提物预防人肝细胞培养物胰岛素抵抗(2 型糖尿病的前兆)的能力,并鉴定了南非钩麻处理调节的基因。
胰岛素和果糖的组合用于在人肝细胞中产生胰岛素抵抗的体外模型,以比较未处理的对照、胰岛素抵抗和南非钩麻处理的胰岛素抵抗培养物。通过葡萄糖摄取、糖异生和细胞培养物中的脂质积累来测量胰岛素抵抗及其由南非钩麻预防。使用 RT(2)Profiler(TM)PCR 阵列的 84 个糖尿病相关基因定量检测基因表达的变化。
胰岛素抵抗的 Chang 肝细胞摄取的 2-[(3)H]-脱氧葡萄糖明显减少(p<0.05),释放到培养基中的葡萄糖更多(p<0.05),细胞内脂质积累更多(p<0.05)。同时用南非钩麻治疗可预防这些胰岛素抵抗参数的发展(p<0.05)。南非钩麻处理的胰岛素抵抗细胞中共有 27 个潜在的南非钩麻基因靶标被显著上调或下调。在囊泡运输中起作用的基因 VAMP3 被胰岛素抵抗下调,被南非钩麻上调。其他 26 个编码囊泡转运蛋白、受体、信号分子、转录因子和代谢酶的基因也被南非钩麻显著调节。
这些结果证实南非钩麻可预防肝细胞胰岛素抵抗。鉴定的基因表达变化表明南非钩麻具有抗糖尿病作用的几种潜在机制,反映了先前在南非钩麻水提物中鉴定的多种生物活性化合物。